Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3821321 | 0.99 | OPRM1 (0.56) | OPRM1OPRL1SLC18A3HRH3TMEM97 | |
| SCHEMBL3991447 | 0.94 | OPRM1 (0.58) | OPRM1OPRL1SLC18A3HRH3TMEM97 | |
| SCHEMBL3991452 | 0.94 | OPRM1 (0.58) | OPRM1OPRL1SLC18A3HRH3TMEM97 | |
| SCHEMBL3990437 | 0.86 | KMT2A (0.44) | OPRM1OPRL1HRH3MEN1KMT2A | |
| SCHEMBL3992914 | 0.86 | OPRM1 (0.38) | OPRM1OPRL1SIGMAR1KMT2AHSD11B1 | |
| SCHEMBL3992958 | 0.85 | NPY1R (0.42) | OPRM1OPRL1CNR2MEN1KMT2A | |
| SCHEMBL3822308 | 0.84 | OPRM1 (0.40) | OPRM1OPRL1SIGMAR1TP53MEN1 | |
| SCHEMBL3824513 | 0.84 | KMT2A (0.43) | OPRM1OPRL1HRH3SIGMAR1KMT2A | |
| SCHEMBL3444664 | 0.84 | OPRM1 (0.53) | OPRM1OPRL1MAPTMEN1KMT2A | |
| SCHEMBL3825485 | 0.84 | NPY1R (0.41) | OPRM1OPRL1TMEM97SIGMAR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507816-B2 | Pharmaceutical preparations comprising substituted beta-aminoalcohols | GRUENENTHAL GMBH (DE) | 2009-03-24 | — | — | US | claimed |
| US-20050020691-A1 | Pharmaceutical preparations comprising substituted beta-aminoalcohols | GRUENENTHAL GMBH (DE) | 2005-01-27 | — | — | US | claimed |
| EP-1496890-A1 | SUBSTITUTED BETA-AMINOALCOHOLS USED AS MEDICAMENTS | Grünenthal GmbH (DE) | 2005-01-19 | — | — | EP | claimed |
| WO-2003051353-A1 | SUBSTITUTED BETA-AMINOALCOHOLS USED AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-06-26 | — | — | WO | claimed |
| US-7507816-B2 | Pharmaceutical preparations comprising substituted beta-aminoalcohols | GRUENENTHAL GMBH (DE) | 2009-03-24 | — | — | US | disclosed |
| US-20050020691-A1 | Pharmaceutical preparations comprising substituted beta-aminoalcohols | GRUENENTHAL GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| EP-1496890-A1 | SUBSTITUTED BETA-AMINOALCOHOLS USED AS MEDICAMENTS | Grünenthal GmbH (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003051353-A1 | SUBSTITUTED BETA-AMINOALCOHOLS USED AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020691-A1 | Pharmaceutical preparations comprising substituted beta-aminoalcohols | ADRB1, ADRB2, ADRA1D | OPRM1 36/4885OPRL1 23/4885SLC18A3 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.